Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: Clopidogrel resistance testing is not routine prior to transcarotid artery revascularization (TCAR) and resistance rates are not well described in this setting despite frequent use of periprocedural clopidogrel. We compared 2 resistance testing modalities to determine the relationship between resistance and stent outcomes.
Methods: Consecutive patients undergoing TCAR at 3 institutions were retrospectively identified. Clopidogrel-resistance testing results and outcomes were described.
Results: A total of 210 patients underwent TCAR from 2018-2022. One hundred fifty four (73%) were on dual antiplatelet therapy (DAPT) for at least 7 days prior to TCAR. Twenty-nine patients were not on DAPT due to therapeutic anticoagulation and most (38/56, 68%) received a loading dose of a second antiplatelet the day of surgery. Twenty-five patients (11.9%) experienced stent thrombosis within 30 days. Patients not on DAPT for at least 7 days prior to surgery were more prone to stent thrombosis (16.7% vs. 10.4%, P = 0.164). More than half (133/210, 63%) of patients underwent resistance testing, 25 with thromboelastography with platelet mapping (TEG-PM), 103 with VerifyNow P2Y12 platelet reactivity assay, and 5 with both. Prevalence of Clopidogrel resistance among tested patients was 41%. In patients tested using both TEG-PM and VerifyNow, agreement was poor (Cohen's Kappa -0.05). Among patients with resistance, 12 (22%) experienced stent thrombosis. Comparatively, 8 (10%) patients without resistance developed thrombosis (P = 0.021). VerifyNow P2Y12 platelet reactivity assay correctly predicted Clopidogrel resistance more accurately than TEG-PM (70% vs. 40%, P = 0.025) and had sensitivity of 56% and specificity of 73% for stent thrombosis.
Conclusions: Our multi-institutional cohort confirms a high rate of Clopidogrel resistance in patients undergoing TCAR, with higher acute stent thrombosis rates noted in patients with resistance. VerifyNow P2Y12 platelet reactivity assays more reliably predict Clopidogrel resistance than TEG-PM.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.avsg.2024.09.031 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Pharmacokinetics and pre-systemic biotransformation of a deuterated clopidogrel-ferulic acid conjugate in rats.
J Pharm Sci
August 2025
School of Life Sciences, Jilin University, Changchun, China. Electronic address:
To address the low biotransformation efficiency and high interindividual variability of clopidogrel (Clop), we developed a novel deuterated Clop-ferulic acid derivative (Dclop-FA), featuring an FA ester pharmacophore at the C2 and a deuterated methyl ester at the C7 position. Pharmacokinetic studies in rats showed that a single oral dose of Dclop-FA achieved 6.0-fold greater systemic exposure to the active metabolite versus equimolar coadministration of Clop and FA.
View Article and Find Full Text PDFPathophysiology of Clopidogrel in Ischemic Stroke, Role of Platelet microRNAs.
Physiol Res
August 2025
Department of Neurology, AGEL Hospital Ostrava-Vítkovice, Ostrava, Czech Republic.
Variation in response to clopidogrel represents a significant clinical challenge in patients with ischemic stroke. Genetic polymorphisms cytochrome P450 2C19 (CYP2C19) are a known cause of resistance to clopidogrel. Platelet microRNAs (miRNAs) can modulate the efficacy of antiplatelet therapy.
View Article and Find Full Text PDFDrug response testing for elective carotid artery stenting: Prevalence of non-response to aspirin and clopidogrel and influence on post-interventional occurrence of cerebral ischemia.
Neuroradiol J
August 2025
Department of Neuroradiology, University Hospital RWTH Aachen, Aachen, Germany.
BackgroundThe patient-associated prevalence of Clopidogrel (CPG)-and Aspirin (ASS)-nonresponse is not well understood and varies depending on the patient population. The influence of responder status for platelet inhibition in patients eligible for carotid artery stenting (CAS) on post-interventional cerebral ischemia is unknown.MethodsWe conducted a retrospective, mono-center analysis of all patients with response-test undergoing elective CAS between 2010 and 2024 and available MRI before and after CAS.
View Article and Find Full Text PDFImproved Platelet Inhibition with Ticagrelor when compared to Clopidogrel in Peripheral Artery Disease Patients.
J Vasc Surg
August 2025
Division of Vascular and Endovascular Surgery, Massachusetts General Hospital, Boston, MA. Electronic address:
Background: Clopidogrel and Ticagrelor are well-known antiplatelet drugs that inhibit P2Y12 receptors. Though Clopidogrel is currently the standard of care for Peripheral Artery Disease (PAD), 25% of patients are known to exhibit drug resistance due to genetic variability. Ticagrelor presents an alternative with reduced susceptibility to genetic variations and has demonstrated superior outcomes in Acute Coronary Syndromes.
View Article and Find Full Text PDFDrug-Induced Insulin Autoimmune Syndrome: A FAERS Database and Network Pharmacology Analysis.
Endocr Metab Immune Disord Drug Targets
August 2025
Department of Pharmacy, Xiangya Hospital, Central South University, Changsha 410005, Hunan, China.
Introduction: Insulin Autoimmune Syndrome (IAS) is a rare yet clinically significant drug-induced adverse reaction, characterized by hypoglycemic episodes caused by insulin autoantibodies. While individual drug associations are documented in case reports, systematic pharmacovigilance analyses supporting drug-induced IAS are lacking in the literature. This study aims to identify drugs associated with IAS through pharmacovigilance analysis and explore potential molecular mechanisms.
View Article and Find Full Text PDF